by EpicentRx | Jan 12, 2024 | Blog, General
This is a companion post to a recently written one entitled, “Blogging About NO Clogging.” That post describes how the EpicentRx lead small molecule, RRx-001 (nibrozetone), releases the gaseous vasodilator, nitric oxide (NO), only under hypoxic/ischemic conditions to...
by EpicentRx | Jan 12, 2024 | Blog
Time and again in conditions like myocardial infarction, hemorrhagic/hypovolemic shock, stroke, pulmonary hypertension, heart failure, diabetes, atherosclerosis, chronic kidney disease, sickle cell disease and others, EpicentRx lead molecule, RRx-001 (nibrozetone),...
by EpicentRx | Jan 11, 2024 | Blog
We’ve been asked several times about our New Year’s resolution(s). Our response? Revolution. Our 2024 resolution is revolution. Revolution through evolution. The revolution is to be carried out against the current despotic regime of widespread toxicity that...
by EpicentRx | Jan 11, 2024 | Blog
Vive la révolution! The immunotherapy revolution. Having begun in 2011 with the approval of the first immune checkpoint inhibitor (ICI), ipilimumab (Yervoy), we predict that 2024 will continue the revolution with the advancement of therapies that reverse resistance to...
by EpicentRx | Jan 10, 2024 | Blog
Call it pettifogging, captious carping, or just plain ol’ nitpicking, but we really hate it when spell check rewrites RRx-001 as “RRX-001” or “RRex-001.” Not that we need any justification, but Rx (not RX or Rex) means prescription or recipe, and plus RRx-001 is a...
